A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
A Phase 1 Non-Randomized, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
Sponsor: Aligos Therapeutics
A PHASE1 clinical study on COVID-19, this trial is completed. The trial is conducted by Aligos Therapeutics and has accumulated 3 data snapshots since 2025. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
3 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Feb 2025 — Nov 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Aligos Therapeutics
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .